Accessibility StatementSkip Navigation STATESVILLE, N.C., Nov. 26, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced that the Company plans to release its second quarter fiscal year 2026 financial results on Wednesday, December 10, 2025 after the close of trading. This information will be available on the Company's website www.kewaunee.com after the release. About Kewaunee Scientific Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the desig ...

Core Insights - Kewaunee Scientific Corporation reported a strong financial performance for the first quarter of fiscal year 2026, with significant increases in sales, earnings, and EBITDA compared to the prior year [2][9]. Financial Performance - Sales for the first quarter were $71,104,000, a 46.9% increase from $48,393,000 in the same quarter last year [2]. - Pre-tax earnings rose to $3,920,000, up 61.3% from $2,430,000 in the prior year [2]. - Net earnings increased to $3,093,000 compared to $2,193,000 in the previous year [2]. - EBITDA for the quarter was $6,320,000, compared to $3,325,000 in the prior year [2]. Segment Performance - Domestic sales reached $54,352,000, a 53.0% increase from $35,523,000 in the prior year [4]. - International sales were $16,752,000, reflecting a 30.2% increase from $12,870,000 in the previous year [5]. - The domestic segment's net earnings were $4,722,000, up from $2,871,000 in the prior year [4]. - The international segment's net earnings increased to $643,000 from $463,000 in the previous year [5]. Order Backlog - The company's order backlog was $205.0 million as of July 31, 2025, compared to $159.4 million on July 31, 2024, and $214.6 million on April 30, 2025 [3]. Corporate Segment - The corporate segment reported a pre-tax net loss of $3,058,000, compared to a loss of $1,992,000 in the prior year [6]. - Corporate segment EBITDA was ($2,311,000), slightly worse than ($2,109,000) in the previous year [6]. Cash and Debt Position - Total cash on hand was $20,441,000, up from $17,164,000 on April 30, 2025 [7]. - Short-term debt decreased to $4,294,000 from $4,773,000 on April 30, 2025 [8]. - Long-term debt was $60,269,000, down from $60,730,000 on April 30, 2025 [8]. Management Commentary - The CEO noted solid performance despite challenging market conditions and indicated expectations of volatility in project delivery timelines for the remainder of fiscal year 2026 [9]. - The company is focused on both organic and inorganic growth, with strategic investments in people, processes, and technology to support future growth [9].

Company Overview - Kewaunee Scientific Corporation, founded in 1906, is a global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products [2] - The company's product offerings include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks [2] - Kewaunee's corporate headquarters is located in Statesville, North Carolina, with sales offices in the United States, India, Saudi Arabia, and Singapore [2] - The company operates three manufacturing facilities in Statesville and one in Bangalore, India, serving both domestic and international markets [2] Recent Developments - Kewaunee Scientific announced plans to release its first quarter fiscal year 2026 financial results on September 10, 2025, after the close of trading [1] - The newly acquired subsidiary, Nu Aire, specializes in manufacturing biological safety cabinets, CO2 incubators, ultralow freezers, and other essential laboratory products [3] - Nu Aire, founded in 1971, has its headquarters and manufacturing facilities in Plymouth, Minnesota, with additional capabilities in Long Lake, Minnesota, and a warehouse partnership in the Netherlands [3] Future Outlook - The company is focused on realizing the benefits of the Nu Aire acquisition, which is expected to enhance its product portfolio and market reach [5]

Core Viewpoint - Kewaunee Scientific Corporation has demonstrated significant growth in both revenue and earnings for the fourth quarter and fiscal year 2025, outperforming the S&P 500 index during the same period [1][2][3]. Revenue & Earnings Performance - Fiscal fourth-quarter net sales increased by 36.1% to $77.1 million from $56.7 million year-over-year [2]. - Adjusted diluted earnings per share (EPS) rose by 25.8% to $1.95 from $1.55 [2]. - For fiscal 2025, net sales totaled $240.5 million, an 18% increase from $203.8 million in the previous year [3]. - Adjusted diluted EPS for the year rose by 28.2% to $5.37 from $4.19 [3]. Segment Highlights - Domestic operations saw a 54.7% increase in fiscal fourth-quarter sales to $55.5 million from $35.9 million [4]. - International sales grew by 3.9% year-over-year in the fiscal fourth quarter to $21.7 million [5]. - The corporate segment reported an adjusted EBITDA loss of $1.4 million, widening from a loss of $956,000 the previous year [6]. Management Commentary - The CEO attributed the strong performance to effective strategy execution and heightened customer demand [7]. - The company acknowledged macroeconomic challenges but highlighted its adaptable culture and partnerships as strengths [8]. Drivers Behind the Results - The acquisition of Nu Aire significantly contributed to revenue and earnings growth, with adjusted operating profit reaching $9.8 million from $5.6 million in the prior year [9]. - The fiscal fourth-quarter adjusted gross profit surged by 69% to $24.7 million from $14.6 million [10]. Guidance - Management expressed optimism for continued growth through organic initiatives and potential future acquisitions [12]. Other Developments - Kewaunee completed the acquisition of Nu Aire on November 1, 2024, which is expected to generate long-term synergies despite short-term costs [13]. - The acquisition led to an increase in long-term debt and a rise in the debt-to-equity ratio to 0.99-to-1 from 0.70-to-1 the previous year [14].